114 related articles for article (PubMed ID: 7537561)
1. Cellular pharmacology and protein binding of phosphoromonothioate and phosphorodithioate oligodeoxynucleotides: a comparative study.
Tonkinson JL; Guvakova M; Khaled Z; Lee J; Yakubov L; Marshall WS; Caruthers MH; Stein CA
Antisense Res Dev; 1994; 4(4):269-78. PubMed ID: 7537561
[TBL] [Abstract][Full Text] [Related]
2. Patterns of intracellular compartmentalization, trafficking and acidification of 5'-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells.
Tonkinson JL; Stein CA
Nucleic Acids Res; 1994 Oct; 22(20):4268-75. PubMed ID: 7937155
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells.
Stein CA; Tonkinson JL; Zhang LM; Yakubov L; Gervasoni J; Taub R; Rotenberg SA
Biochemistry; 1993 May; 32(18):4855-61. PubMed ID: 8490026
[TBL] [Abstract][Full Text] [Related]
4. Distribution of phosphodiester and phosphorothioate oligonucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization.
Yaida Y; Nowak TS
Regul Pept; 1995 Oct; 59(2):193-9. PubMed ID: 8584754
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides as therapeutic agents--is the bullet really magical?
Stein CA; Cheng YC
Science; 1993 Aug; 261(5124):1004-12. PubMed ID: 8351515
[TBL] [Abstract][Full Text] [Related]
6. Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell lines.
Rubenstein M; Slobodskoy L; Mirochnik Y; Guinan P
Methods Find Exp Clin Pharmacol; 2002 Dec; 24(10):649-52. PubMed ID: 12616956
[TBL] [Abstract][Full Text] [Related]
7. Design of potent phosphorothioate antisense oligonucleotides directed to human interleukin 10 gene product and their evaluation of antisense activity in U937 cells.
Arima H; Takahashi M; Aramaki Y; Sakamoto T; Yuda K; Akiyama K; Goto T; Tsuchiya S
Pharm Res; 1999 Aug; 16(8):1163-71. PubMed ID: 10468015
[TBL] [Abstract][Full Text] [Related]
8. Phosphorothioate-phosphodiester oligonucleotide co-polymers: assessment for antisense application.
Ghosh MK; Ghosh K; Cohen JS
Anticancer Drug Des; 1993 Feb; 8(1):15-32. PubMed ID: 8386513
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of some properties of a phosphorodithioate oligodeoxyribonucleotide for antisense application.
Ghosh MK; Ghosh K; Dahl O; Cohen JS
Nucleic Acids Res; 1993 Dec; 21(24):5761-6. PubMed ID: 8284226
[TBL] [Abstract][Full Text] [Related]
10. Antisense inhibitory effect: a comparison between 3'-partial and full phosphorothioate antisense oligonucleotides.
Galderisi U; Di Bernardo G; Melone MA; Galano G; Cascino A; Giordano A; Cipollaro M
J Cell Biochem; 1999 Jul; 74(1):31-7. PubMed ID: 10381259
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides.
Normanno N; Bianco C; Damiano V; de Angelis E; Selvam MP; Grassi M; Magliulo G; Tortora G; Bianco AR; Mendelsohn J; Salomon DS; Ciardiello F
Clin Cancer Res; 1996 Mar; 2(3):601-9. PubMed ID: 9816209
[TBL] [Abstract][Full Text] [Related]
12. Stereo-enriched phosphorothioate oligodeoxynucleotides: synthesis, biophysical and biological properties.
Yu D; Kandimalla ER; Roskey A; Zhao Q; Chen L; Chen J; Agrawal S
Bioorg Med Chem; 2000 Jan; 8(1):275-84. PubMed ID: 10968287
[TBL] [Abstract][Full Text] [Related]
13. p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.
Janicek MF; Angioli R; Unal AD; Sevin BU; Madrigal M; Estape R; Averette HE
Gynecol Oncol; 1997 Jul; 66(1):94-102. PubMed ID: 9234928
[TBL] [Abstract][Full Text] [Related]
14. Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2'-O-propyl modifications.
McKay RA; Cummins LL; Graham MJ; Lesnik EA; Owens SR; Winniman M; Dean NM
Nucleic Acids Res; 1996 Feb; 24(3):411-7. PubMed ID: 8602351
[TBL] [Abstract][Full Text] [Related]
15. Antisense knockdown of PKC-alpha using LNA-oligos.
Hansen JB; Westergaard M; Thrue CA; Giwercman B; Oerum H
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1607-9. PubMed ID: 14565477
[TBL] [Abstract][Full Text] [Related]
16. Use of partially phosphorothioated "antisense" oligodeoxynucleotides for sequence-dependent modulation of hematopoiesis in culture.
Ehrlich G; Patinkin D; Ginzberg D; Zakut H; Eckstein F; Soreq H
Antisense Res Dev; 1994; 4(3):173-83. PubMed ID: 7849488
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D
Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer.
Rubenstein M; Anderson KM; Tsui P; Guinan P
Med Hypotheses; 2006; 67(6):1375-80. PubMed ID: 16870352
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice.
DeLong RK; Nolting A; Fisher M; Chen Q; Wickstrom E; Kligshteyn M; Demirdji S; Caruthers M; Juliano RL
Antisense Nucleic Acid Drug Dev; 1997 Apr; 7(2):71-7. PubMed ID: 9149842
[TBL] [Abstract][Full Text] [Related]
20. Nucleotide pyrophosphatase/phosphodiesterase 1 is responsible for degradation of antisense phosphorothioate oligonucleotides.
Wójcik M; Cieślak M; Stec WJ; Goding JW; Koziołkiewicz M
Oligonucleotides; 2007; 17(1):134-45. PubMed ID: 17461770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
